Analysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $5.43

Gossamer Bio, Inc. (NASDAQ:GOSS) has been given a consensus recommendation of “Hold” by the ten brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.4286.

Several research firms have recently commented on GOSS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Tuesday, April 21st. Wedbush reaffirmed a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. The Goldman Sachs Group cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Barclays cut Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd.

Gossamer Bio Stock Up 1.4%

NASDAQ GOSS opened at $0.35 on Thursday. The stock’s 50-day moving average price is $0.48 and its 200-day moving average price is $1.97. Gossamer Bio has a 52 week low of $0.32 and a 52 week high of $3.87. The company has a market capitalization of $82.05 million, a P/E ratio of -0.47 and a beta of 2.16.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $7.53 million. Research analysts anticipate that Gossamer Bio will post -0.5 EPS for the current year.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: A securities class action has been filed alleging investor losses tied to Gossamer’s February 2026 PROSERA Phase 3 failure; the suit cites the trial miss that triggered an ~80% share drop earlier this year. This is the core complaint that spawned the subsequent solicitation notices. Article: Hagens Berman class action notice
• Negative Sentiment: Multiple law firms (Faruqi & Faruqi, Glancy Prongay, Levi & Korsinsky, Rosen, Pomerantz, Hagens Berman, Schall, Gross, others) have issued investor alerts and investor‑recovery solicitations, increasing public scrutiny and the likelihood of consolidated litigation. The broad outreach raises the chance of costly discovery and settlement activity. Article: Faruqi & Faruqi reminder
• Negative Sentiment: The accelerated cadence of notices emphasizes the upcoming June 1, 2026 lead‑plaintiff deadline; if a lead plaintiff is appointed, coordinated litigation could proceed quickly and create additional operational distractions and expense for Gossamer. Investors should watch filings and the court docket for consolidation or motions. Article: Pomerantz investor alert

Institutional Trading of Gossamer Bio

Several institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in shares of Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock worth $42,000 after purchasing an additional 54,439 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in shares of Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after purchasing an additional 50,666 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares in the last quarter. Invesco Ltd. grew its holdings in Gossamer Bio by 36.0% during the 4th quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock valued at $1,485,000 after buying an additional 126,823 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its holdings in Gossamer Bio by 52.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after buying an additional 8,239 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.